Zoekresultaten - Ángel Guerrero‐Zotano

Verfijn jouw resultaten
  1. 1
    Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery

    Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery door Ángel Guerrero‐Zotano, Carlos L. Arteaga

    Gepubliceerd in 2017
    Volledige tekst
    Revisão
    Toevoegen aan favorieten
    Bewaard in:
  2. 2
    Optimizing therapeutic approaches for HR+/HER2- advanced breast cancer: clinical perspectives on biomarkers and treatment strategies post-CDK4/6 inhibitor progression

    Optimizing therapeutic approaches for HR+/HER2- advanced breast cancer: clinical perspectives on biomarkers and treatment strategies post-CDK4/6 inhibitor progression door J.M. Cejalvo Andujar, Francisco Ayala de la Peña, Mireia Margelí Vila, Javier Pascual, Pablo Tolosa, C. Pagès, Mónica Cuenca, Ángel Guerrero‐Zotano

    Gepubliceerd in 2025
    Volledige tekst
    Revisão
    Toevoegen aan favorieten
    Bewaard in:
  3. 3
    Identification of minimal residual disease using the clonesight test for ultrasensitive ctDNA detection to anticipate late relapse in early breast cancer

    Identification of minimal residual disease using the clonesight test for ultrasensitive ctDNA detection to anticipate late relapse in early breast cancer door Iñaki Comino‐Méndez, Jesús Velasco-Suelto, Javier Pascual, Esperanza López-López, María Elena Quirós-Ortega, Celia Gaona-Romero, Alejandro Martín-Muñoz, Patricia Losana, Yanira Heredia, Emilio Alba, Ángel Guerrero‐Zotano

    Gepubliceerd in 2025
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  4. 4
    A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole

    A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole door Zaida García‐Casado, Ángel Guerrero‐Zotano, Antonio Llombart–Cussac, Ana Calatrava, Antonio Fernández‐Serra, Amparo Ruiz-Simón, Joaquín Gavilá, Miguel Ángel Climent, Sergio Almenar, José Cervera-Deval, Josefina Campos, Carlos Vázquez Albaladejo, Antonio Llombart‐Bosch, Vicente Guillém, José Antonio López‐Guerrero

    Gepubliceerd in 2010
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  5. 5
    Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial

    Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial door Dhivya R. Sudhan, Luis J. Schwarz, Ángel Guerrero‐Zotano, Luigi Formisano, Mellissa J. Nixon, Sarah Croessmann, Paula I. González-Ericsson, Melinda E. Sanders, Justin M. Balko, Francesca Avogadri-Connors, Richard E. Cutler, Alshad S. Lalani, Richard Bryce, Alan Auerbach, Carlos L. Arteaga

    Gepubliceerd in 2018
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  6. 6
    Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER+ Breast Cancer

    Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER+ Breast Cancer door Alberto Servetto, Rahul K. Kollipara, Luigi Formisano, Chang‐Ching Lin, Kyung‐min Lee, Dhivya R. Sudhan, Paula I. González-Ericsson, Sumanta Chatterjee, Ángel Guerrero‐Zotano, Saurabh Mendiratta, Hiroaki Akamatsu, Nicholas G. James, Roberto Bianco, Ariella B. Hanker, Ralf Kittler, Carlos L. Arteaga

    Gepubliceerd in 2021
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  7. 7
    Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer

    Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer door Kyung‐min Lee, Ángel Guerrero‐Zotano, Alberto Servetto, Dhivya R. Sudhan, Chang‐Ching Lin, Luigi Formisano, Valerie M. Jansen, Paula I. González-Ericsson, Melinda E. Sanders, Thomas Stricker, Ganesh V. Raj, Kevin M. Dean, Reto Fiolka, Lewis C. Cantley, Ariella B. Hanker, Carlos L. Arteaga

    Gepubliceerd in 2020
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  8. 8
    Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer

    Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer door Jordi Rodón, José Alejandro Pérez Fidalgo, Ian E. Krop, Howard A. Burris, Ángel Guerrero‐Zotano, Carolyn D. Britten, Carlos Becerra, Jan H.M. Schellens, Donald Richards, Martin Schüler, Maysa Abu‐Khalaf, Faye M. Johnson, Malcolm Ranson, Jeff Edenfield, Antonio P. Silva, Wolfgang Hackl, Cornelia Quadt, David Demanse, Vincent Duval, José Baselga

    Gepubliceerd in 2018
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  9. 9
    MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation

    MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation door Kyung‐min Lee, Jennifer M. Giltnane, Justin M. Balko, Luis J. Schwarz, Ángel Guerrero‐Zotano, Katherine E. Hutchinson, Mellissa J. Nixon, Mónica V. Estrada, Violeta Sánchez, Melinda E. Sanders, Taekyu Lee, Henry Gómez, Aña Lluch, José Alejandro Pérez Fidalgo, Melissa M. Wolf, Gabriela Andrejeva, Jeffrey C. Rathmell, Stephen W. Fesik, Carlos L. Arteaga

    Gepubliceerd in 2017
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  10. 10
    Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study

    Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study door Ángel Guerrero‐Zotano, J. M. Perez-Garcia, Manuel Ruíz‐Borrego, Begoña Bermejo, Miguel Gil‐Gil, J. de la Haba, E. Alba Conejo, Vanesa Quiroga, Vicente Carañana, Ander Urruticoechea, Selena Morales, Meritxell Bellet, Ángela Antón, María Fernández-Abad, Pedro Sánchez‐Rovira, Laura Calabuig, Jhudit Pérez‐Escuredo, M Sampayo-Cordero, Javier Cortés, A Llombart-Cussac

    Gepubliceerd in 2024
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  11. 11
    <i>CCNE1</i>and<i>PLK1</i>Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer

    <i>CCNE1</i>and<i>PLK1</i>Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer door Ángel Guerrero‐Zotano, Stefania Belli, Christoph Zielinski, Miguel Gil‐Gil, Antonio Fernández‐Serra, Manuel Ruíz-Borrego, Eva Ciruelos, Javier Pascual, Montserrat Muñoz, Begoña Bermejo, Mireia Margelí Vila, Antonio Antón, Laura Murillo, Bella Nissenbaum, Yuan Liu, Jesús Herránz, Daniel Fernández-García, Rosalía Caballero, José Antonio López‐Guerrero, Roberto Bianco, Luigi Formisano, Nicholas C. Turner, Miguel Martín

    Gepubliceerd in 2023
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  12. 12
    Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer

    Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer door Luigi Formisano, Kimberly M. Stauffer, Christian D. Young, Neil E. Bhola, Ángel Guerrero‐Zotano, Valerie M. Jansen, Mónica M. Estrada, Katherine E. Hutchinson, Jennifer M. Giltnane, Luis J. Schwarz, Yao Lu, Justin M. Balko, Olivier Déas, Stefano Cairo, Jean-Gabriel Judde, Ingrid A. Mayer, Melinda E. Sanders, Teresa C. Dugger, Roberto Bianco, Thomas Stricker, Carlos L. Arteaga

    Gepubliceerd in 2017
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  13. 13
    Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers

    Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers door Dhivya R. Sudhan, Ángel Guerrero‐Zotano, Helen Won, Paula I. González-Ericsson, Alberto Servetto, Mariela Huerta-Rosario, Dan Ye, Kyung‐min Lee, Luigi Formisano, Yan Guo, Qi Liu, Lisa N. Kinch, Monica Red Brewer, Teresa C. Dugger, James P. Koch, Michael J. Wick, Richard E. Cutler, Alshad S. Lalani, Richard Bryce, Alan Auerbach, Ariella B. Hanker, Carlos L. Arteaga

    Gepubliceerd in 2020
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  14. 14
    Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

    Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine door Karama Asleh, Aña Lluch, Angela Goytain, Carlos H. Barrios, Xue Q. Wang, Laura Torrecillas, Dongxia Gao, Manuel Ruíz-Borrego, Samuel Leung, José Bines, Ángel Guerrero‐Zotano, José Á. García-Sáenz, Juan Miguel Cejalvo, Jesús Herránz, Roberto Torres, Juan de la Haba-Rodríguez, Francisco Ayala de la Peña, Henry Gómez, Federico Rojo, Torsten O. Nielsen, Miguel Martín

    Gepubliceerd in 2022
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  15. 15
    Data from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

    Data from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine door Karama Asleh, Aña Lluch, Angela Goytain, Carlos H. Barrios, Xue Q. Wang, Laura Torrecillas, Dongxia Gao, Manuel Ruíz-Borrego, Samuel Leung, José Bines, Ángel Guerrero‐Zotano, José Á. García-Sáenz, Juan Miguel Cejalvo, Jesús Herránz, Roberto Torres, Juan de la Haba-Rodríguez, Francisco Ayala de la Peña, Henry Gómez, Federico Rojo, Torsten O. Nielsen, Miguel Martín

    Gepubliceerd in 2023
    Volledige tekst
    Pré-impressão
    Toevoegen aan favorieten
    Bewaard in:
  16. 16
    Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial

    Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial door Frankie A. Holmes, Beverly Moy, Suzette Delaloge, Stephen Chia, Bent Ejlertsen, Janine Mansi, Hiroji Iwata, Michael Gnant, Marc Buyse, Carlos H. Barrios, Tajana Silovski, Robert Šeparović, Anna Bashford, Ángel Guerrero Zotano, Neelima Denduluri, Debra A. Patt, Erhan Gökmen, Ira Gore, John W. Smith, Sibylle Loibl, Norikazu Masuda, Z. Tomasevic, Katarína Petráková, Daniel DiPrimeo, Alvin Wong, Miguel Martín, Arlene Chan

    Gepubliceerd in 2023
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  17. 17
    Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer

    Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer door Juan Miguel Cejalvo, Eduardo Martínez de Dueñas, Patricia Galván, Susana García‐Recio, Octavio Burgués Gasión, Laia Paré, Silvia Antolín, Rosella Martinello, Isabel Blancas, Bárbara Adamo, Ángel Guerrero‐Zotano, Montserrat Muñoz, Paolo Nucíforo, María Vidal, Ramón M. Pérez, José I. Chacón López-Muniz, Rosalía Caballero, Vicente Peg, Eva Carrasco, Federico Rojo, Charles M. Perou, Javier Cortés, Vincenzo Adamo, Joan Albanell, Roger R. Gomis, Aña Lluch, Aleix Prat

    Gepubliceerd in 2017
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  18. 18
    FOXC1 expression predicts capecitabine efficacy in triple-negative breast cancer patients from the GEICAM_CIBOMA trial

    FOXC1 expression predicts capecitabine efficacy in triple-negative breast cancer patients from the GEICAM_CIBOMA trial door Federico Rojo, Clive R. Taylor, Carlos H. Barrios, Laura Torrecillas, Manuel Ruíz-Borrego, Sandra Pérez‐Buira, José Bines, Ángel Guerrero‐Zotano, José A. García‐Sáenz, Roberto Torres, Juan de la Haba-Rodríguez, Francisco Ayala de la Peña, Henry Gómez, Antonio Llombart‐Cussac, María Rodríguez de la Borbolla, José Manuel Baena-Cañada, Agustí Barnadas, Lourdes Calvo, Jesús Herránz, Raúl Rincón, Rosalía Caballero, Begoña Bermejo, Partha S. Ray, Miguel Martín

    Gepubliceerd in 2025
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  19. 19
    Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM study

    Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM study door Regina Peña-Enríquez, Begoña Bermejo, Marina Pollán, Alejandra Díaz‐Chacón, Yolanda Jeréz Gilarranz, José Ponce, António Fernández, Blanca Cantos Sánchez de Ibargüen, Ana Santaballa Bertrán, Elena Gálve, Álvaro Jiménez-Arranz, Yolanda Fernández, M. Perez, Susana de la Cruz, Antonio Antón-Torres, Fernando Moreno, María Vidal, María Helena López-Ceballos, Isabel Blancas, María José Echarri, Raúl Rincón, Rosalía Caballero, Ángel Guerrero-Zotano, Silvia Guil‐Luna, Juan de la Haba-Rodríguez

    Gepubliceerd in 2025
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  20. 20
    Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study

    Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study door Eduardo Martínez de Dueñas, Ana Lluch Hernández, Ángel Guerrero Zotano, Ramón María Pérez Carrión, José Ignacio Chacón, Silvia Antolín, Ángela López Rodrí­guez, José Alejandro Pérez Fidalgo, Jaime Ferrer-Lozano, Octavio Burgués Gasión, Eva Carrasco Carrascal, Andrés Hernando Capilla, Isabel Blancas, Montserrat Muñoz, María Helena López de Ceballos Reyna, A. Oltra Ferrando, Noelia Martínez-Jáñez, V. Carañana Ballerini, A. Antón Torres, Gustavo Catalán, José Á. García-Sáenz, S. Menjón, Ana M. González-Angulo

    Gepubliceerd in 2014
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:

Zoekinstrumenten: